CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the publication of data from a preclinical study evaluating oligonucleotide-based compounds containing novel synthetic immune stimulatory motifs that act as agonists of Toll-like Receptor (TLR) 9. These results offer insight into specific chemical modifications of TLR9 agonists and their ability to stimulate immune responses. The paper entitled “Agonists of Toll-like Receptor 9 Containing Synethetic Dinucleotide Motifs” is published in the Journal of Medicinal Chemistry (online November 8, 2007).
